IDEXX Laboratories, Inc. $IDXX Stock: First Citizens Bank & Trust Co. Decreases Stake

First Citizens Bank & Trust Co. decreased its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 16.7% during the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 22,537 shares of the company’s stock after selling 4,522 shares during the quarter. First Citizens Bank & Trust Co.’s holdings in IDEXX Laboratories were worth $11,769,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of IDXX. Signal Advisors Wealth LLC purchased a new stake in IDEXX Laboratories during the 3rd quarter valued at approximately $265,000. B. Riley Wealth Advisors Inc. purchased a new position in shares of IDEXX Laboratories in the third quarter worth $207,000. NorthCrest Asset Manangement LLC lifted its holdings in shares of IDEXX Laboratories by 57.9% in the third quarter. NorthCrest Asset Manangement LLC now owns 627 shares of the company’s stock worth $322,000 after buying an additional 230 shares in the last quarter. Haven Capital Group Inc. lifted its holdings in shares of IDEXX Laboratories by 1.4% in the third quarter. Haven Capital Group Inc. now owns 11,648 shares of the company’s stock worth $6,082,000 after buying an additional 156 shares in the last quarter. Finally, Schaper Benz & Wise Investment Counsel Inc. WI boosted its position in shares of IDEXX Laboratories by 1.4% during the third quarter. Schaper Benz & Wise Investment Counsel Inc. WI now owns 49,884 shares of the company’s stock worth $26,049,000 after acquiring an additional 678 shares during the last quarter. Institutional investors own 87.84% of the company’s stock.

IDEXX Laboratories Stock Down 0.7%

Shares of NASDAQ:IDXX opened at $520.31 on Wednesday. The company has a market cap of $40.99 billion, a price-to-earnings ratio of 36.59, a PEG ratio of 2.80 and a beta of 1.55. IDEXX Laboratories, Inc. has a 12 month low of $500.61 and a 12 month high of $769.98. The company has a 50-day moving average price of $536.72 and a 200 day moving average price of $552.17. The company has a current ratio of 1.17, a quick ratio of 0.87 and a debt-to-equity ratio of 0.19.

IDEXX Laboratories (NASDAQ:IDXX) last released its earnings results on Tuesday, August 4th. The company reported $4.27 EPS for the quarter, beating analysts’ consensus estimates of $3.94 by $0.33. IDEXX Laboratories had a return on equity of 71.96% and a net margin of 25.03%. The firm had revenue of $1.22 billion for the quarter, compared to analysts’ expectations of $1.20 billion. During the same quarter in the prior year, the firm posted $3.50 earnings per share. The company’s quarterly revenue was up 9.7% on a year-over-year basis. IDEXX Laboratories has set its FY 2026 guidance at 14.690-14.940 EPS. As a group, equities research analysts predict that IDEXX Laboratories, Inc. will post 14.81 earnings per share for the current year.

Analysts Set New Price Targets

IDXX has been the subject of several research analyst reports. Barclays cut their target price on shares of IDEXX Laboratories from $800.00 to $710.00 and set an “overweight” rating for the company in a research note on Tuesday, August 11th. Wall Street Zen downgraded shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Sunday, July 12th. Citigroup raised their price objective on IDEXX Laboratories from $650.00 to $670.00 and gave the company a “neutral” rating in a research report on Wednesday, August 5th. Weiss Ratings raised IDEXX Laboratories from a “hold (c)” rating to a “hold (c+)” rating in a report on Thursday, October 8th. Finally, KeyCorp assumed coverage on IDEXX Laboratories in a research report on Monday. They issued a “sector weight” rating on the stock. Six research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company. According to data from MarketBeat, IDEXX Laboratories currently has an average rating of “Moderate Buy” and an average target price of $747.00.

Key IDEXX Laboratories News

Here are the key news stories impacting IDEXX Laboratories this week:

• Positive Sentiment: KeyCorp projects earnings growth beyond fiscal 2026, estimating EPS of $16.58 for FY2027 and $18.74 for FY2028. Those forecasts imply continued earnings expansion for IDEXX’s veterinary diagnostics business. KeyBanc initiates coverage of IDEXX Laboratories at sector weight
• Neutral Sentiment: KeyCorp’s quarterly forecasts are $3.70 EPS for Q3 2026, $3.34 for Q4 2026, $3.93 for Q1 2027, $4.61 for Q2 2027, $4.22 for Q3 2027 and $3.81 for Q4 2027. The firm estimates FY2026 EPS at $14.77, close to the broader consensus of $14.81.
• Negative Sentiment: KeyCorp’s FY2026 EPS estimate of $14.77 is modestly below the $14.81 consensus, while its Sector Weight rating offers no clear catalyst for investors seeking an upgrade or stronger near-term outlook. IDEXX also trades at a relatively elevated valuation, with a reported price-to-earnings ratio above 36.

Insider Activity at IDEXX Laboratories

In related news, Director Lawrence D. Kingsley sold 2,203 shares of IDEXX Laboratories stock in a transaction dated Friday, September 4th. The stock was sold at an average price of $532.08, for a total value of $1,172,172.24. Following the completion of the sale, the director directly owned 9,568 shares in the company, valued at $5,090,941.44. The trade was a 18.72% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Corporate insiders own 0.79% of the company’s stock.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) develops and provides diagnostic, information technology and water-testing products and services. The company primarily serves the companion animal veterinary market, helping veterinary practices diagnose and manage diseases through laboratory testing, in-house analyzers, diagnostic kits, imaging systems, software and related consumables.

IDEXX’s companion animal offerings include its IDEXX Reference Laboratories, IDEXX VetLab instruments and software, SNAP rapid tests, and practice-management and data solutions.